Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27563906 | 0.76 | GAA (0.36) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL5663335 | 0.70 | TSHR (0.40) | GAATSHRALDH1A1LMNAHSD17B10 | |
| Diethyl Hydrogen Phosphate SCHEMBL27712045 | 0.69 | GAA (0.38) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL8980111 | 0.69 | ALDH1A1 (0.34) | GAATSHRALDH1A1HSD17B10PPARD | |
| SCHEMBL4283889 | 0.69 | TP53 (0.34) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL11128475 | 0.69 | GAA (0.44) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL9625829 | 0.69 | GAA (0.44) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL27966463 | 0.68 | TSHR (0.41) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL9142867 | 0.68 | PPARD (0.33) | TSHRALDH1A1PPARD | |
| SCHEMBL3895322 | 0.67 | TSHR (0.42) | TSHRPPARDTP53TDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404836-B2 | 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | GAA 683/4885TSHR 561/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.